 |
Adnexus is leading the discovery and development of a novel class of targeted medicines, we call Adnectins™. Adnectins are designed to either block or stimulate the action of specific proteins to fight diseases across a broad range of therapeutic areas including oncology and immunology. Our proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines. |
Adnexus is a wholly owned |